FDFan Du

Fan Du

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Fan Du has a total of 21 co-authors. Here are the top co-authors by number of shared publications:

  • Lan Bai

    School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, PR China

    2 shared publications
  • Miao He

    School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, 510006, PR China

    2 shared publications
  • Qiao-Yan Yi

    Department of Clinical Pharmacy, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital Shandong Engineering and Technology Research Center for Pediatric Drug Development, Shandong Medicine and Health Key Laboratory of Clinical Pharmacy Jinan China

    2 shared publications
  • Wen-Yao Zhang

    College of Longping Agricultural, College of Biology, State Key Laboratory of Chemo and Biosensing, Hunan Research Center of the Basic Discipline for Cell Signaling, and National Center of Technology Innovation for Saline-Alkali Tolerant Rice, Hunan University , Changsha 410082

    2 shared publications
  • Fenglin Chen

    Department of Gastroenterology and Fujian Institute of Digestive Disease, Fujian Medical University Union Hospital, Fuzhou, China

    1 shared publication
  • Guangbin Jiang

    Guangxi Key Laboratory of Electrochemical and Magnetochemical Function Materials, College of Chemistry and Bioengineering, Guilin University of Technology, 12 Jiangan Road, Guilin 541004, China

    1 shared publication

Latest Publications

  • 5‐Lipoxygenase promotes epithelial–mesenchymal transition through the ERK signaling pathway in gastric cancer

    by Hao Lin, Junyong Weng, Haitao Mei, Mingkai Zhuang, Xinzhu Xiao, Fan Du, Liying Lin, Juhua Wu, Zhixin Chen, Yuehong Huang, et al.

    Background and Aim: 5‐Lipoxygenase has been reported to enhance cell proliferation, migration, and invasion. Epithelial–mesenchymal transition is considered an important process for tumor metastasis and invasion.Methods: The 5‐lipoxygenase expression levels and the prognoses in patients with gastric cancer were evaluated by immunohistochemistry and by the log‐rank test on Kaplan–Meier curves. We established 5‐lipoxygenase‐overexpressed and 5‐lipoxygenase‐silenced gastric cancer cells and measured migration, invasion, and epithelial–mesenchymal transition makers to examine the role of 5‐lipoxygenase in gastric cancer in vitro. In vivo, 5‐lipoxygenase‐overexpressed gastric cancer cells were administered into mice by subcutaneous injection, intraperitoneal injection or splenic intravenous injection to study the proliferation or metastasis of 5‐lipoxygenase in mice. Using the extracellular signal‐regulated kinase pathway inhibitor U0126 and activator tumor growth factor‐β, we investigated the mechanism of epithelial–mesenchymal transition induced by 5‐lipoxygenase in gastric cancer cells.Results: 5‐Lipoxygenase was upregulated in gastric cancer tissues and was related to poor overall survival in gastric cancer patients. 5‐Lipoxygenase promoted gastric cancer cell proliferation, migration, and invasion and induced the process of epithelial–mesenchymal transition in gastric cancer cells. In the nude mouse model, mice with gastric cancer tumors overexpressing 5‐LOX had a faster tumor growth rate and more severe abdominal and liver metastases than the control group. Inhibition of extracellular signal‐regulated kinase signaling by U0126 or activation by tumor growth factor‐β neutralized the effect of 5‐LOX overexpression or silencing on epithelial–mesenchymal transition.Conclusion: 5‐Lipoxygenase promotes epithelial–mesenchymal transition in gastric cancer by activating the extracellular signal‐regulated kinase signaling pathway.


  • Evaluation of anticancer activity in vitro and in vivo of iridium(iii) polypyridyl complexes

    by Miao He, Qiao-Yan Yi, Wen-Yao Zhang, Lan Bai, Fan Du, Yi-Ying Gu, Yun-Jun Liu, Peng Wei

    In this study, we designed and synthesized three new iridium(III) complexes [Ir(ppy)2(dmdppz)](PF6) (ppy = 2-phenylpyridine) (1), [Ir(bzq)2(dmdppz)](PF6) (bzq = benzo[h]quinolone) (2) and [Ir(piq)2(dmdppz)](PF6) (piq = 1-phenylisoquinoline, dmdppz = 5,8-dimethoxylpyrido[3,2-a:2′,3′-c]phenazine) (3). All the complexes were tested for anticancer activity by the 3-(4,5-dimethylthiazole)-2,5-diphenyltetrazolium bromide (MTT) method. These complexes showed high anticancer activity against SGC-7901 cells, and the IC50 values are 4.1 ± 0.5 for 1, 0.7 ± 0.1 for 2 and 0.6 ± 0.2 μM for 3. Additionally, complex 3 can inhibit the tumor growth in xenograft nude mice in vivo with an inhibitory percentage of tumor growth of 48.21%. Morphological studies show that the cells treated with the complexes exhibit typical apoptotic morphological characteristics such as nuclear fragmentation and chromatin condensation. Quantitative analysis by flow cytometry showed that the apoptosis rate increased sharply after the cells were exposed to the complexes, and NAC (an inhibitor that inhibits the production of ROS) can inhibit the increase of the apoptosis rate. Cell cycle studies show that complex 1 can block the SGC-7901 cell cycle at the G0/G1 phase, and complexes 2 and 3 can cause cycle arrest at the S phase. All the complexes can increase the intracellular reactive oxygen species level, and reduce the mitochondrial membrane potential, which further prompts the release of cytochrome c. In addition, the complexes can damage DNA and cause disruption of the microtubule network. In conclusion, the complexes can effectively induce cancer cell apoptosis and may be potential anticancer agents for gastric cancer.